SMS-Oncology Signs a Clinical Trial Collaboration with Cytovation to Treat Solid Tumors

 SMS-Oncology Signs a Clinical Trial Collaboration with Cytovation to Treat Solid Tumors

SMS-Oncology Signs a Clinical Trial Collaboration with Cytovation to Treat Solid Tumors

Shots:

  • The companies collaborate to conduct P-I/II clinical trial assessing CyPep-1 in patients to treat advanced solid cancers. SMS-Oncology will focus on developing protocol and giving guidance on patient inclusion criteria plus investigational sites for further movement to clinic
  • The P-I/II multicenter trial will be conducted in Europe evaluating safety, efficacy & PK or intratumoral of CyPep-1 in patients with advanced solid cancers enrolling 18 patients, with its expected initiation in Q4’19. Additionally, Cytovation is currently starting first-in-human trial with intratumoral injection of CyPep-1, aiming to reach first in patient (FPI) in H2’19  
  • Cytovation’s CyPep-1 is lead investigational first-in-class lytic agent targeted for solid tumors in both injectable and cream formulations, currently being evaluated in P-I trial in patients with HPV-induced cutaneous tumors (warts)

Click here to read full press release/ article | Ref: Globe NewsWire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post